Search Clinical Trials in the European Union

Duration
Visits
Safety phase (I)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
481-500 of 936 trials

IKS03 for Advanced B Cell Non-Hodgkin Lymphoma

We are studying the effects of IKS03 in patients with advanced B cell non-Hodgkin lymphoma. The goal is to see if it can improve treatment outcomes compared to standard therapies.

Advanced B cell Non-Hodgkin Lymphoma>2 yearsSafety phase (I)Oncology

Advanced Cancer: JK06 Antibody Drug

We are testing a new drug called JK06 for patients with advanced cancer that cannot be removed by surgery. The study aims to evaluate its safety and how well it may work in treating this type of cancer.

Unresectable, Locally Advanced or Metastatic CancerSafety phase (I)Efficacy phase (II)No PlaceboOncology

Gastrointestinal Cancers: Patritumab Deruxtecan Study

We are evaluating a new treatment for people with gastrointestinal cancers to see if it is safe and effective. This study aims to understand how well it works compared to existing options.

Colorectal CancerHepatocellular CarcinomaBiliary Tract Cancer>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsInvestigational MedicinesOncology

CRISPR CAR Therapy for Blood and Solid Cancers

We are studying the long-term safety and effectiveness of CRISPR CAR cellular therapies in patients with hematological and solid malignancies. This research aims to provide insights into how well this treatment works over time.

Solid TumorsHematologic Malignancies>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesHematologyOncology

Cochlear Implant Surgery: Testing VSF1.01 Treatment

We are investigating the safety of a new treatment for patients receiving cochlear implants. This study aims to see if it can reduce surgery-related trauma and improve hearing outcomes.

Hearing Loss1-2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboOtolaryngology

Advanced Cancer: BI 1831169 and Anti-PD-1 Therapy

We are testing different doses of a new medication alone and with an anti-PD-1 antibody for people with advanced solid tumors. This study aims to see how well these treatments work together.

Solid Tumors>2 yearsSafety phase (I)Oncology

GRT7040: First-in-Human Safety Study

We are testing a new medication called GRT7040 in healthy volunteers to see how safe it is and how the body processes it. This study aims to gather important information before it can be used in patients.

Pain6-12 monthsSafety phase (I)AllergologyCardiologyDermatologyDiabetologyEndocrinologyGastroenterologyGynecology and ObstetricsHematologyHepatologyInfectious DiseasesInternal MedicineNephrologyNeurologyOncologyOrthopedics and TraumatologyOtolaryngologyPediatricsPsychiatryPulmonologyRheumatologyUrology

Triple-Negative Breast Cancer: NECVAX-NEO1 Treatment

We are studying the safety and effects of NECVAX-NEO1 added to standard PD-1 inhibitor therapy for patients with triple-negative breast cancer. This trial aims to see if the new treatment can enhance cancer response and improve outcomes.

Triple Negative Breast Cancer6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology

MSC Therapy for Kidney Transplant Recipients

We are exploring whether a new therapy using stem cells can improve health outcomes for people who have received a kidney transplant. This study aims to understand its potential benefits in this patient group.

Kidney Transplant RejectionBiopsy-Proven Acute Rejection (BPAR)1-2 yearsSafety phase (I)Internal MedicineNephrology

Advanced Solid Tumors: Repotrectinib Study

We are testing a new treatment called repotrectinib for patients with advanced solid tumors that have specific genetic changes. The study aims to evaluate its safety and effectiveness in improving tumor response.

Advanced Solid Tumors3-6 monthsSafety phase (I)Efficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncology

Mantle Cell Lymphoma: Ibrutinib and Venetoclax Study

We are studying the effects of Ibrutinib alone and in combination with Venetoclax in patients with untreated mantle cell lymphoma. The goal is to see how well these treatments reduce disease levels in the body.

Untreated Mantle Cell Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Fosfomycin: New Extended Infusion Method

We are studying a new way to give fosfomycin to see if it improves how the body absorbs the medication. This trial is for individuals needing antibiotic treatment.

Healthy Participants>2 yearsSafety phase (I)Infectious Diseases

Relapsing Multiple Sclerosis: YTB323 Treatment Study

We are testing a new treatment called YTB323 for people with Relapsing Multiple Sclerosis who have had ongoing disease activity despite previous therapies. The study aims to assess its safety and effects on disease progression.

Relapsing Multiple Sclerosis1-2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesNeurology

BP1.7881: Safety Study in Healthy Volunteers

We are testing a new medication to see how safe it is and how the body handles it. This study will also look at its effects on heart function in healthy individuals.

Eosinophilic EsophagitisSafety phase (I)AllergologyGastroenterology

Advanced Solid Tumors: VERT-002 Study

We are studying a new anticancer drug, VERT-002, for patients with advanced solid tumors, including lung cancer with MET alterations. The trial aims to assess its safety and how well it may work.

Metastatic Non-Small Cell Lung CancerSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Facial Lines: IPN10200 Treatment Study

We are studying a new treatment for adults with moderate to severe upper facial lines to see if it improves their appearance compared to a placebo. The trial will assess both safety and effectiveness of the treatment.

Frown Lines6-12 monthsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesDermatology

HIV Control: Pomalidomide Study

We are studying whether pomalidomide can help control HIV in people on treatment who take a break from their medication. The trial also examines its effects on the immune system and HIV persistence.

HIV-1 Infection3-6 monthsSafety phase (I)Efficacy phase (II)11-15 visitsStandard MedicinesInfectious DiseasesInternal Medicine

Head and Neck or Liver Cancer: Testing New Drug Combinations

We are studying whether combinations of BI 765063, ezabenlimab, chemotherapy, cetuximab, and BI 836880 can help people with head and neck or liver cancer. This research aims to find more effective treatment options.

Head and Neck Squamous Cell Carcinoma (HNSCC)Hepatocellular Carcinoma>2 yearsSafety phase (I)Oncology

Advanced Solid Tumors: INCB123667 Study

We are testing a new drug, INCB123667, alone and with other cancer therapies for people with advanced solid tumors. The goal is to understand its effects and potential benefits in treating these cancers.

Advanced Cancer>2 yearsSafety phase (I)Oncology

Anorexia Nervosa: Sertraline Pharmacokinetics Study

We are exploring how a single dose of sertraline is processed in the body of female patients with anorexia nervosa compared to healthy women. This study may help improve treatment approaches for anorexia.

Anorexia Nervosa>2 yearsSafety phase (I)Psychiatry